Cargando…
Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS)
Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at 2 g/m(2)/day. Initial IFOS dose (12 g/m(2)) was a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698138/ https://www.ncbi.nlm.nih.gov/pubmed/17251655 http://dx.doi.org/10.1155/SRCM/2006/26986 |
_version_ | 1782131226157514752 |
---|---|
author | López-Pousa, A. Martín, J. Montalar, J. de las Peñas, R. García del Muro, J. Cruz, J. Maurel, J. Escudero, P. Casado, A. Buesa, J. M. the Spanish Group for Research on Sarcomas (GEIS), |
author_facet | López-Pousa, A. Martín, J. Montalar, J. de las Peñas, R. García del Muro, J. Cruz, J. Maurel, J. Escudero, P. Casado, A. Buesa, J. M. the Spanish Group for Research on Sarcomas (GEIS), |
author_sort | López-Pousa, A. |
collection | PubMed |
description | Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at 2 g/m(2)/day. Initial IFOS dose (12 g/m(2)) was adjusted to 10, 13, or 14 g/m(2) according to toxicity. Results. Seventy patients received 277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose increased, 30% decreased, and 48% delivered at 12 g/m(2). Toxicity grade 4 occurred on granulocytes (67% of patients) or platelets (19%), 54% had febrile neutropenia, 31% grade 3/4 asthenia, and 26% abandoned the study due to toxicity. Three toxic deaths occurred. In 57 non-GIST patients objective activity was 45.6% (95% CI, 32 to 58%). Conclusion. At least 4 cycles were tolerated by 71% of patients, most receiving DXR 50 mg/m(2) plus IFOS 10–12 g/m(2), with substantial toxicity. |
format | Text |
id | pubmed-1698138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-16981382007-01-17 Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS) López-Pousa, A. Martín, J. Montalar, J. de las Peñas, R. García del Muro, J. Cruz, J. Maurel, J. Escudero, P. Casado, A. Buesa, J. M. the Spanish Group for Research on Sarcomas (GEIS), Sarcoma Clinical Study Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients with soft tissue sarcomas. Methods. DXR was given IV bolus and IFOS by continuous infusion at 2 g/m(2)/day. Initial IFOS dose (12 g/m(2)) was adjusted to 10, 13, or 14 g/m(2) according to toxicity. Results. Seventy patients received 277 cycles (median 3 cycles, range 1–10), 34% with IFOS dose increased, 30% decreased, and 48% delivered at 12 g/m(2). Toxicity grade 4 occurred on granulocytes (67% of patients) or platelets (19%), 54% had febrile neutropenia, 31% grade 3/4 asthenia, and 26% abandoned the study due to toxicity. Three toxic deaths occurred. In 57 non-GIST patients objective activity was 45.6% (95% CI, 32 to 58%). Conclusion. At least 4 cycles were tolerated by 71% of patients, most receiving DXR 50 mg/m(2) plus IFOS 10–12 g/m(2), with substantial toxicity. Hindawi Publishing Corporation 2006 2006-09-19 /pmc/articles/PMC1698138/ /pubmed/17251655 http://dx.doi.org/10.1155/SRCM/2006/26986 Text en Copyright © 2006 A. López-Pousa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study López-Pousa, A. Martín, J. Montalar, J. de las Peñas, R. García del Muro, J. Cruz, J. Maurel, J. Escudero, P. Casado, A. Buesa, J. M. the Spanish Group for Research on Sarcomas (GEIS), Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS) |
title | Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) |
title_full | Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) |
title_fullStr | Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) |
title_full_unstemmed | Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) |
title_short | Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in
Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study
of the Spanish Group for Research on Sarcomas (GEIS) |
title_sort | phase ii trial of doxorubicin plus escalated high-dose ifosfamide in
patients with advanced soft tissue sarcomas of the adult: a study
of the spanish group for research on sarcomas (geis) |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698138/ https://www.ncbi.nlm.nih.gov/pubmed/17251655 http://dx.doi.org/10.1155/SRCM/2006/26986 |
work_keys_str_mv | AT lopezpousaa phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT martinj phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT montalarj phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT delaspenasr phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT garciadelmuroj phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT cruzj phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT maurelj phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT escuderop phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT casadoa phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT buesajm phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis AT thespanishgroupforresearchonsarcomasgeis phaseiitrialofdoxorubicinplusescalatedhighdoseifosfamideinpatientswithadvancedsofttissuesarcomasoftheadultastudyofthespanishgroupforresearchonsarcomasgeis |